GHSR-1a Agonist Peptide Research: Myocyte Cell Models and GH Axis Studies

GHSR-1a Agonist Peptide Research: Myocyte Cell Models and GH Axis Studies

GHSR-1a Agonist Peptide Research: Myocyte Cell Models and GH Axis Studies

Receptor Pharmacology and Mechanism of Action

GHSR-1a agonist peptides demonstrate specific binding characteristics at the growth hormone secretagogue receptor subtype 1a, a G-protein coupled receptor (GPCR) belonging to the rhodopsin-like receptor family. In vitro pharmacological studies utilizing competitive radioligand binding assays reveal nanomolar binding affinity constants (Kd) ranging from 0.1 to 1.5 nM in recombinant cell expression systems. These compounds function through orthosteric site engagement, displacing endogenous ligands and activating downstream signalling cascades.

The molecular mechanism involves conformational changes in the transmembrane helical domains upon ligand binding, leading to G-protein subunit dissociation and subsequent second messenger system activation. Functional cell-based assays demonstrate robust calcium mobilization responses with EC50 values typically observed between 0.5-5.0 nM in HEK293 cells expressing recombinant GHSR-1a receptors.

Myocyte Cell Model Systems

Primary Myocyte Cultures

Primary myocyte cell models provide physiologically relevant experimental platforms for investigating GHSR-1a agonist activity. Isolated cardiomyocytes and skeletal muscle myocytes express endogenous GHSR-1a receptors, enabling direct pharmacological characterization without genetic manipulation. These cell systems demonstrate concentration-dependent responses to peptide exposure, with measurable changes in intracellular calcium dynamics and cyclic adenosine monophosphate (cAMP) accumulation.

Patch-clamp electrophysiology studies in primary myocyte preparations reveal peptide-induced alterations in ion channel conductance, particularly affecting L-type calcium channels and potassium channel subtypes. Time-course experiments indicate rapid onset of action within 30 seconds of peptide application, with peak responses occurring at 2-5 minutes post-exposure.

Immortalized Myocyte Cell Lines

C2C12 myoblast cell lines transfected with GHSR-1a constructs serve as reproducible model systems for high-throughput screening applications. These cell models maintain consistent receptor expression levels across passage numbers, enabling standardized pharmacological profiling. Fluorescence-based calcium imaging assays in these systems demonstrate robust, reproducible responses to GHSR-1a agonist peptides across multiple experimental replicates.

GH Axis Signalling Pathways

cAMP-PKA Pathway Activation

GHSR-1a receptor activation triggers adenylyl cyclase stimulation through Gs-protein coupling, resulting in elevated intracellular cAMP concentrations. Enzyme-linked immunosorbent assays (ELISA) measuring cAMP accumulation show dose-dependent responses with EC50 values correlating closely with binding affinity measurements. Protein kinase A (PKA) activation downstream of cAMP elevation leads to phosphorylation of transcription factors including cAMP response element-binding protein (CREB).

Phospholipase C-IP3 Signalling

Dual G-protein coupling mechanisms enable GHSR-1a activation to stimulate phospholipase C (PLC) activity through Gq/11 pathways. This results in inositol 1,4,5-trisphosphate (IP3) generation and subsequent calcium release from endoplasmic reticulum stores. Fluorescent calcium indicators in cell-based assays demonstrate biphasic calcium responses, with initial rapid spikes followed by sustained elevation phases.

Enzyme Kinetics and Binding Characteristics

Saturation Binding Studies

Saturation binding experiments using radiolabeled ligands reveal single-site binding kinetics with Hill coefficients near unity, indicating non-cooperative binding interactions. Scatchard plot analysis confirms single receptor population binding with consistent Bmax values across different cell model systems. Temperature-dependent binding studies demonstrate optimal binding affinity at physiological temperatures (37°C).

Competition Binding Assays

Competitive displacement studies using various GHSR-1a ligands establish relative binding affinities and selectivity profiles. These assays reveal peptide-specific binding characteristics, with some compounds demonstrating enhanced selectivity over related receptor subtypes. Kinetic binding experiments measure association (kon) and dissociation (koff) rate constants, providing comprehensive binding kinetic profiles.

Downstream Effector Systems

Transcriptomic analysis of peptide-treated cell cultures reveals upregulation of immediate early genes including c-fos and egr-1, indicating successful pathway activation. Protein expression studies demonstrate time-dependent changes in signalling cascade components, with maximum responses occurring 4-6 hours post-treatment. These molecular endpoints provide quantitative measures of pathway engagement and cellular response magnitude.

Research Summary

GHSR-1a agonist peptides demonstrate potent receptor binding activity with nanomolar affinities in multiple cell model systems. Primary and immortalized myocyte cultures provide physiologically relevant platforms for mechanistic studies, revealing dual G-protein signalling pathway activation and robust calcium mobilization responses. Comprehensive enzyme kinetic analysis establishes binding characteristics essential for structure-activity relationship development and compound optimization in pharmaceutical research applications.

All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML